Lupin Ltd receives approval from the USFDA to market its generic Loteprednol Etabonate ophthalmic suspension for seasonal allergic conjunctivitis relief.
The approval is for the abbreviated new drug application for Loteprednol Etabonate ophthalmic suspension, 0.2%, as a generic equivalent to Alrex ophthalmic suspension, 0.2% by Bausch & Lomb Inc.
Lupin’s Pithampur facility in India will manufacture the approved product. Loteprednol Etabonate ophthalmic suspension, 0.2%, addresses the temporary relief of signs and symptoms of seasonal allergic conjunctivitis.
The product’s estimated annual sales in the US market are USD 29.1 million, according to IQVIA MAT October 2023 data.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
